SC‐560 and mofezolac isosteres as new potent COX‐1 selective inhibitors with antiplatelet effect
Sign Up to like & getrecommendations! Published in 2023 at "Archiv der Pharmazie"
DOI: 10.1002/ardp.202200549
Abstract: Selective cyclooxygenase (COX)‐1 inhibitors can be employed as potential cardioprotective drugs. Moreover, COX‐1 plays a key role in inflammatory processes and its activity is associated with some types of cancer. In this work, we designed… read more here.
Keywords: new potent; cox; potent cox; mofezolac isosteres ... See more keywords
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01346
Abstract: The receptor tyrosine kinase AXL is a promising target for anticancer drug discovery. Herein, we describe the discovery of 3-aminopyrazole derivatives as new potent and selective AXL kinase inhibitors. One of the representative compounds, 6li,… read more here.
Keywords: new potent; aminopyrazole derivatives; axl; discovery aminopyrazole ... See more keywords
New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Microbiology"
DOI: 10.3389/fmicb.2017.00775
Abstract: The increasing prevalence of multidrug-resistant bacteria urges the development of new antibacterial agents. With a broad spectrum activity, antimicrobial peptides have been considered potential antibacterial drug leads. Using bioinformatic tools we have previously shown that… read more here.
Keywords: new potent; membrane targeting; targeting antibacterial; antibacterial peptides ... See more keywords